CD86 and neoplasm: While the frequency of infiltrating antigen presenting cells in the tumor was not significantly impacted by the therapies (Figure 6a), the costimulatory molecule CD86 was upregulated in CD103+ DCs after PLE‐IL‐12‐NPs or free IL‐12 therapy (Figure 6b), suggesting an enhanced activation of those cells.